From Globe Newswire:

The Single-Cell Genome Sequencing Market size was valued at $2.6 billion in 2024, with a projected CAGR of 16.9% to reach $10.8 billion by 2034. Single-cell genome sequencing (SCGS) analyzes the complete genetic makeup of individual cells, providing insights into cancer research, cell differentiation, and more. Advancements in sequencing technologies and growing demands in healthcare are driving market growth. Challenges include managing complex datasets and the need for sturdy quality control procedures. The market is expanding due to industry players’ cooperation and increased funding for sophisticated equipment. However, barriers include high costs and privacy and security concerns. Detailed segmentation by type, technology, application, end-user, and region, with regional analysis highlighting market dynamics and growth drivers. North America currently leads the market due to financial support and use of genomic analysis products. The market is expected to expand with the rise in chronic diseases and the collaboration between research institutes and market participants. Major companies include ThermoFisher Scientific, Illumina, and Bio-Rad. The market is expected to grow due to R&D expenditures by pharmaceutical and biotechnology businesses and increasing single cell analysis in cancer research and immunology.



Read more: Single-Cell Genome Sequencing Market Size & Share to Exceed